Drug
Vosoritide
Vosoritide: highest development phase Phase 3, developed by BioMarin Pharmaceutical. 5 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- BioMarin Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| Vosoritide NCT07073014 | Phase 3 | Hypochondroplasia |
| Vosoritide Injection NCT06382155 | Phase 2 | Idiopathic Short Stature |
| Vosoritide Injection NCT06668805 | Phase 2 | Noonan Syndrome |
| Vosoritide NCT07126262 | Phase 2 | Hypochondroplasia |
| vosoritide NCT04554940 | Phase 2 | Achondroplasia |
Latest
No recent events.
Follow Vosoritide on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.